William Blair Investment Management LLC Makes New Investment in Establishment Labs Holdings Inc. $ESTA

William Blair Investment Management LLC acquired a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 714,051 shares of the company’s stock, valued at approximately $61,273,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in ESTA. BlackRock Inc. acquired a new stake in Establishment Labs in the second quarter worth about $135,752,000. Rice Hall James & Associates LLC bought a new stake in Establishment Labs in the second quarter valued at approximately $48,134,000. Goldman Sachs Group Inc. raised its stake in Establishment Labs by 117.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after buying an additional 438,206 shares during the period. Viking Global Investors LP acquired a new stake in shares of Establishment Labs during the second quarter worth about $14,669,000. Finally, Soleus Capital Management L.P. acquired a new stake in Establishment Labs during the 2nd quarter worth approximately $9,050,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ESTA shares. Citigroup raised Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a research note on Thursday, August 13th. Canaccord Genuity Group set a $105.00 price target on shares of Establishment Labs in a research report on Thursday, August 6th. Needham & Company LLC raised their price objective on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. Finally, TD Cowen boosted their price target on Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.25.

Establishment Labs Stock Performance

NASDAQ ESTA opened at $72.67 on Friday. Establishment Labs Holdings Inc. has a 1 year low of $36.53 and a 1 year high of $97.59. The firm’s 50 day simple moving average is $86.19 and its 200 day simple moving average is $74.84. The company has a current ratio of 3.84, a quick ratio of 2.52 and a debt-to-equity ratio of 12.11. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -55.47 and a beta of 1.07.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The business had revenue of $67.54 million for the quarter, compared to analyst estimates of $65.79 million. During the same period last year, the firm posted ($0.57) EPS. Establishment Labs’s quarterly revenue was up 31.7% on a year-over-year basis. As a group, research analysts expect that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.